LEXICON PHARMACEUTICALS, INC. Cash Flow Statement
LXRX|12 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 12 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$162M
FY2025
Free Cash Flow
-$162M
FY2025
Capital Expenditures
$470,000
Cash used for long-term assets
Dividends Paid
N/A
FY2025
LEXICON PHARMACEUTICALS, INC. used $162M in operating cash flow and negative free cash flow of $162M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$177.1M | -$101.9M | -$87.8M | -$58.6M | -$131.4M | -$4.7M | -$100.3M | -$104.1M | -$110.2M | -$116.2M | -$101.8M | -$82.8M |
| Depreciation & Amortization | $554.0K | $427.0K | $292.0K | $2.9M | $2.1M | $727.0K | $1.9M | $2.9M | $4.2M | $4.9M | $5.4M | $6.2M |
| Operating Cash Flow | -$161.9M | -$88.9M | -$87.0M | -$143.0M | -$175.6M | $184.8M | -$75.6M | -$91.1M | -$94.5M | -$87.9M | -$82.4M | -$89.0M |
| Capital Expenditures | $470.0K | $1.3M | $1.2M | $87.0K | $231.0K | $910.0K | $80.0K | $1.7M | $492.0K | $1.2M | $1.1M | $369.0K |
| Free Cash Flow | -$162.4M | -$90.2M | -$88.2M | -$143.1M | -$175.9M | $183.9M | -$75.7M | -$92.8M | -$95.0M | -$89.1M | -$83.5M | -$89.4M |
| Share Buybacks | - | $864.0K | $2.7M | $1.0M | $621.0K | $357.0K | $887.0K | $873.0K | $285.0K | $108.0K | $149.0K | $88.0K |
| FCF Margin | -13485.6% | -64875.5% | -29610.1% | -596.2% | -221.9% | 141.4% | -331.2% | -4176.4% | -8719.2% | -4821.2% | -1701.3% | -835.4% |